Pacira price target raised to $71 from $69 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Pacira BioSciences to $71 from $69 and keeps a Buy rating on the shares post the Q4 results. The analyst says the company’s sales guidance was conservative due to pandemic and inflation-related macro headwinds. A "very long" Exparel growth runway, Zilretta, and upside optionality or Iovera and the early-stage pipeline make Pacira a "potential very attractive strategic acquisition target," the analyst tells investors in a research note.